identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Jankowska, Ewa A ^a   Filippatos, Gerasimos S ^b   von Haehling, Stephan ^c,d   Papassotiriou, Jana ^e   Morgenthaler, Nils G ^e   Cicoira, Mariantonietta ^f   Schefold, Joerg C ^c   Rozentryt, Piotr ^g   Ponikowska, Beata ^h   Doehner, Wolfram ^c   Banasiak, Waldemar ^a   Hartmann, Oliver ^e   Struck, Joachim ^e   Bergmann, Andreas ^e   Anker, Stefan D ^c,i   Ponikowski, Piotr ^a  

^a MILITARY HOSPITAL   (Poland)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e BRAHMS AG   (Germany)

^f UNIVERSITY OF VERONA   (Italy)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h WROCLAW MEDICAL UNIVERSITY   (Poland)

ⁱ IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOXY TERMINAL PRO ENDOTHELIN 1; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1 DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROENDOTHELIN 1; PROTEIN PRECURSOR;

ADULT; AGE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL TIME; AGED; BLOOD; CHRONIC DISEASE; MIDDLE AGED; RISK;

AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; ENDOTHELIN-1; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; RISK;

EID: 79251581599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014506     Document Type: Article

References (34)

1. Marasciulo FL, Montagnani M, Potenza MA (2006) Endothelin-1: the yin and yang on vascular function. Curr Med Chem 13: 1655-1665.
2. Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF (2006) Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111: 508-531.
3. Van Beneden R, Gurné O, Selvais PL, Ahn SA, Robert AR, et al. (2004) Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 10: 490-495.
4. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, et al. (1997) Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18: 254-258.
5. Swedberg K, Cleland J, Dargie H (2005) Guidlines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the ESC. Eur Heart J 26: 1115-1140.
6. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, et al. (2007) Comparison of midregional pro-atrial natriuretic peptide with Nterminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 50: 1973-1980.
7. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, et al. (2010) Midregion pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55: 2062-2076.
8. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, et al. (2010) Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 12: 484-491.
9. Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, et al. (2000) Comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail 6: 201-207.
10. Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, et al. (1995) Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 76: 803-808.
11. Isnard R, Pousset F, Trochu J, Chafirovskaïa O, Carayon A, et al. (2000) Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 86: 417-421.
12. Gardner RS, Chong V, Morton I, McDonagh TA (2005) N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 7: 253-260.
13. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, et al. (1999) Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20: 1799-1807.
14. Weitzberg E, Ahlborg G, Lundberg JM (1991) Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 180: 1298-1303.
15. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, et al. (1988) Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endotheliumderived relaxing factor. Proc Natl Acad Sci U S A 85: 9797-9800.
16. Ferro CJ, Spratt JC, Haynes WG, Webb DJ (1998) Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97: 2323-2330.
17. Rossi GP, Seccia TM, Albertin G, Pessina AC (2000) Measurement of endothelin: clinical and research use. Ann Clin Biochem 37: 608-626.
18. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 52: 1144-1151.
19. Struck J, Morgenthaler NG, Bergmann A (2005) Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 26: 2482-2486.
20. Harrell FE (2001) Regression modeling strategies. New York: Springer.
21. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves from the same cases. Radiology 148: 839-843.
22. Sugden PH, Clerk A (2005) Endothelin signalling in the cardiac myocyte and its pathophysiological relevance. Curr Vasc Pharmacol 3: 343-351.
23. Adlbrecht C, Hülsmann M, Strunk G, Berger R, Mörtl D, et al. (2009) Prognostic value of plasma midregional pro-adrenomedullin and C-terminalpro- endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 11: 361-366.
24. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, et al. (2010) Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 43: 714-719.
25. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, et al. (2010) The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 12: 338-347.
26. Adlbrecht C, Hülsmann M, Strunk G, Berger R, Mörtl D, et al. (2009) Prognostic value of plasma midregional pro-adrenomedullin and C-terminalpro- endothelin-1 in chronic heart failure outpatients. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 11: 361-366.
27. Stanek B, Frey B, Hülsmann M, Koller-Strametz J, Hartter E, et al. (1997) Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure. Transplant Proc 29: 595-596.
28. Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, et al. (2001) Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38: 436-442.
29. Masson S, Latini R, Anand IS, Barlera S, Judd D, et al. (2006) The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 12: 375-380.
30. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, et al. (1996) Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27: 633-641.
31. Hülsmann M, Stanek B, Frey B, Sturm B, Putz D, et al. (1998) Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32: 1695-1700.
32. Berger R, Strecker K, Huelsmann M, Moser P, Frey B, et al. (2003) Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transplant 22: 1037-1045.
33. Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, et al. (2007) Cterminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J 154: 736-742.
34. Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, et al. (2008) Long-term prognostic value of midregional pro-adrenomedullin and C-terminal proendothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med 46: 204-211.